IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer

Lorelei A. Mucci, ScD; Jacob Vinson, MHA; Theresa Gold, BS, MS; Travis Gerke, ScD; Julie Filipenko, MSc; Rebecca M. Green, BS; Simon G. Anderson, PhD, MBBC; Simone Badal, PhD; Anders Bjartell, MD, PhD; Kim N. Chi, MD; Ian D. Davis, PhD; Deborah Enting, MD; André P. Fay, MD, PhD; John Lazarus, MD; Joaquin Mateo, MD; Ray McDermott, MD, PhD; Folakemi T. Odedina, PhD; David Olmos, MD, PhD; Aurelius Omlin, MD; Ademola A. Popoola, MD; Camille Ragin, PhD; Robin Roberts, MD; Kjell M. Russnes, MD, PhD; Charles Waihenya, MD; Konrad H. Stopsack, MD; Terry Hyslop, PhD; Paul Villanti, LLB; David Olmos, MD, PhD; Aurelius Omlin, MD; Ademola A. Popoola, MD; Camille Ragin, PhD; Robin Roberts, MD; Kjell M. Russnes, MD, PhD; Charles Waihenya, MD; Konrad H. Stopsack, MD; Terry Hyslop, PhD; Paul Villanti, LLB; Philip W. Kantoff, MD; and Daniel J. George, MD on behalf of the IRONMAN Global Team

PURPOSE

To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population.

PATIENTS AND METHODS

Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires.

RESULTS

Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service.

CONCLUSION

To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.

INTRODUCTION

Globally, 1.4 million people are diagnosed annually with prostate cancer and 487,000 die of the disease.\(^1\) In the United States, 3.6 million people are prostate cancer survivors,\(^2\) of whom an estimated 180,000 are living with advanced prostate cancer, defined as de novo metastatic hormone-sensitive prostate cancer (mHSPC) at diagnosis; cancers that have progressed to mHSPC after local therapy, and cancers that have progressed to castration-resistant prostate cancer (CRPC). Given the lack of population-level data on patients with advanced prostate cancer, this number is an estimate and the exact number globally is unknown.

The survivorship needs for advanced prostate cancer are distinct from localized disease. These patients are at greatest risk of cancer death\(^3\) and experience poorer quality of life because of the severity of disease and its therapies. The treatment landscape has changed considerably over the past decade with 11 new therapies approved in the United States, each of which is associated with a modest survival advantage (Appendix Table A1).\(^4–15\) There is variability globally in access to these newer therapies, whereas some patients are using older lines of therapies. There is a lack of clear consensus on the optimal treatment patterns in the advanced disease setting and likely variability in treatment patterns across practices.\(^15\) There is a paucity of data on real-world quality of life, risk of adverse events or comorbidities, and the potential impact of lifestyle factors on outcomes for patients with advanced prostate cancer.

IRONMAN (International Registry for Men with Advanced Prostate Cancer; ClinicalTrials.gov identifier:...
NCT03151629) was designed to address the outstanding issues for people with advanced prostate cancer (Fig 1). IRONMAN is a prospective, international registry recruiting a minimum of 5,000 patients with advanced prostate cancer (Table 1 and Fig 2) from 16 countries—the United States, Australia, Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, and the United Kingdom (Fig 3). These initial 16 countries were selected on the basis of existing partnerships and the need to enhance participation in clinical studies by people of African ancestry.16,17 Within each country, we have sought to enroll patients from representative clinical centers to enroll individuals from diverse backgrounds. Patients will be followed for at least 5 years. The longer-term goal will be to expand the countries included in IRONMAN through new partnerships and additional funding. The overarching principle is to make this a lasting resource for the cancer research and clinical communities.

**Patients and Methods**

**Governance and Working Groups**

IRONMAN has a governance structure to facilitate the study conduct and use of its resulting data. IRONMAN features working groups that work synergistically with the Executive Committee, the Clinical and Data Coordinating Center (The Prostate Cancer Clinical Trials Consortium, PCCTC), and the Scientific Advisory Committee (country lead investigators, industry funders as nonvoting members, and the advocacy community; Fig 4). The Executive Committee oversees all aspects of IRONMAN and is composed of the Principal Investigators, the PCCTC Chief Executive Officer, and the Executive Director of Programs at the Movember Foundation. The Executive Committee meets biweekly to review milestones, research proposals, and incorporate scientific advancements throughout the study.

Working groups are composed of investigators, study staff, patient advocates, and other scientists and clinicians within the IRONMAN community. The Diversity Working Group meets monthly to discuss barriers and strategies to enhance enrollment of a racially and ethnically diverse population.17 The Advocacy Working Group provides the patient perspective in all areas of IRONMAN. The Lower- and Middle-Income Countries (LMICs) and Small Island Developing States (SIDSs) Working Group was established to address the unique needs of patients recruited in the Caribbean and Africa and more broadly address oncology needs in these countries. The Biostatistics/Data Science Working Group brings statistical expertise, playing an essential role in assessing data quality and implementing analytic plans from investigators. The Biospecimen Working Group ensures high-quality biospecimen and biomarker collections and evaluates proposals for specimen use. Finally, the Patient-Reported Outcome Measures (PROMs) Working Group and the Physician Questionnaire Working Group monitor compliance of survey collection and address the respective data domains.

**Fig 1.** Objectives of the IRONMAN registry. CRPC, castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer.
The PCCTC, a leader in the coordination of multicenter prostate cancer studies, is the global clinical and data coordinating center for IRONMAN. IRONMAN leverages the PCCTC’s partnerships and infrastructure to manage the registry successfully and efficiently. Each participating country has a designated lead investigator and coordinator, whose institution serves as the local sponsor and coordinating center for their respective country. The PCCTC works closely with country leads to maintain regulatory oversight, patient privacy, and data quality.

Under-Represented Populations

An unmet challenge in prostate cancer is the well-known racial disparity among people of African ancestry.18,19 In the United States, Black patients are more likely to present with advanced-stage prostate cancer20-23 and are 2.1 times more likely to die of prostate cancer compared with White patients.24 A similar disparity exists in the Caribbean. For example, Barbados has the second highest prostate cancer mortality rates in the world. However, several recently FDA-approved prostate cancer therapies are unavailable or inaccessible in LMICs and SIDSs.

Despite racial differences, clinical trials have generally had low enrollment of Black patients. In an analysis of 72 prostate cancer trials,16 96% of patients were White. There is also a documented under-representation in clinical trials for patients living in rural areas despite higher mortality.25,26 Similarly, disparities in prostate cancer outcomes exist among US veterans, where cumulative prostate cancer-specific mortality is higher in patients treated in Veterans Affairs (VA) Medical Centers compared with the general population.27 IRONMAN aims to bridge gaps in knowledge through enrollment of a diverse population guided by the Diversity, LMIC/SIDS, and Advocacy Working Groups17 and through a global lens to enable equal benefit for all.

Participating Countries and Sites

As of July 2022, IRONMAN is open and enrolling in 12 of 16 planned countries at 109 sites, with 14 additional sites planned for activation. US sites include NCI-designated cancer centers, community oncology practices, large group

---

**TABLE 1. Definition and Timing of Newly Diagnosed mHSPC or CRPC in the IRONMAN Study**

| Characteristic | mHSPC | MO/M1 CRPC |
|---------------|-------|------------|
| **Definition** | Metastatic disease M1a, b, or c stage as defined by the American Joint Committee on Cancer at diagnosis or progressing after localized disease diagnosis | Rising PSA indicating progressing disease or new metastatic disease while on ADT (or orchectomy) or with the castrate level of testosterone as determined by the investigator |
| **Timing** | Not more than 90 days of active systemic therapy (including ADT) at the time of consent | Not more than 90 days of continuous life-prolonging (in the opinion of the investigator) systemic therapy for CRPC at the time of consent |
| **Notes** | If the patient received ADT (for any length of time) before current systemic therapy, documented recovery of testosterone is required as determined by the investigator | Prior systemic therapy for any length of time for mHSPC is allowed for patients currently with CRPC. Continuous ADT in the castration-resistant setting is allowed |

Abbreviations: ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.
urology practices, and VA Medical Centers. Sites were selected to create breadth in the cohort across race/ethnicity, rural and urban populations, socioeconomic backgrounds, and geographic regions and include a sizable number of veterans. Each country has a diverse clinical setting on the basis of mixed local practices.

**Informed Consent and Eligibility**

The informed consent, protocol, and patient-facing materials are approved by local regulatory/ethics committees before site accrual. Patients who meet the eligibility criteria (Fig 5) are invited to enroll. The informed consent form allows collection of demographic and health information, future contacts, release of medical records including clinically significant adverse events, questionnaires, and collection of blood and genetic sequencing results. Patients are given opt-in opportunities for future research via access to their existing tissue and imaging assessments. The informed consent form and questionnaires have been translated into 14 languages and culturally adapted to the local customs of participating sites.

**Data Domains and Collection Methods**

Guidelines from the International Consortium for Health Outcomes Measurement Advanced Prostate Cancer Working Group and Prostate Cancer Working Group were integrated to optimize data collection methods and

---

**FIG 3.** Countries with participating IRONMAN sites.

**FIG 4.** Scientific oversight and governance of the IRONMAN registry. LMIC, low- and middle-income countries; PCCTC, Prostate Cancer Clinical Trials Consortium; PROMs, patient-reported outcome measures; SIDSs, small island developing states.
IRONMAN patients must meet the following criteria at study entry:

1. Willing and able to provide written informed consent and privacy authorization for the release of personal health information
2. Age 21 years or older
3. Histologic or cytologic confirmation of prostate cancer OR both metastatic disease typical of prostate cancer (ie, involving bone or pelvic/extrapelvic or para-aortic lymph nodes) AND a serum concentration of PSA > 20 ng/mL
4. Meet the definition of mHSPC or CRPC with not more than 90 days of active systemic therapy for that disease state at the time of consent
5. No current or prior nonprostate cancer requiring systemic therapy within the past 2 years

**FIG 5.** Eligibility criteria. CRPC, castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PSA, prostate-specific antigen.

assessments. Figure 2 outlines the timing and types of data collected. Data are gleaned from medical records, pathology reports, questionnaires, blood biospecimens, and physician questionnaires. IRONMAN leverages regular clinical visits of patients with advanced prostate cancer, which allows standardized assessments via participating sites.

Clinical data are captured via an Electronic Data Capture web-based platform. The PCCTC conducts automated edit checks, manual queries, and audit trails to ensure accurate, complete data collection. Demographics, PROMs, and patient-reported experience measures (PREMs) are captured via the electronic TrueNTH platform. On study registration, site staff enter the participant’s e-mail address for those who consent to use TrueNTH. TrueNTH then prompts patients to complete questionnaires by automatic e-mail reminders where patients can access the questionnaires as they come due. Some patients and sites have elected to use paper questionnaires. All study data are transmitted via secure Internet connection from participating sites to a secure central database using encryption modalities.

**Biospecimens**

Baseline and longitudinal blood specimens (Fig 2 and Table 2) are collected and then processed, aliquoted, and batch shipped to the global biorepository based at the Dana-Farber/Harvard Cancer Center Population Sciences Laboratory Support Core. Each ex-US country has a local biorepository where specimens are collected and stored before shipment to the United States. Baseline blood specimens are drawn after informed consent and not later than 90 days after beginning therapy. Follow-up collections are taken at the time of first change in treatment or at month 12, whichever occurs first. In addition, blood specimens are collected at each subsequent change in treatment because of progression of disease. A detailed laboratory manual with instructions on sample collection, processing, storage, and shipping has been developed. The unique patient identification number, date and time of blood draw, and originating tube are recorded for each blood draw. DNA extractions are periodically undertaken to assess DNA integrity for future biomarker studies. Use of biospecimens is governed by the Biospecimen Working Group and Executive Committee.

**Patient-Reported Information**

Demographic and epidemiologic data are collected at baseline including the following: height, weight (current and at age 40 years), smoking and other tobacco use, alcohol, marital status, living arrangement, education, employment status, physical activity, walking pace, sedentary behavior, use of multivitamins and supplements, race/ethnicity, military service, and family history of cancer (prostate, ovarian, breast, colon, melanoma, and pancreas) including family relation and age at cancer diagnosis. PROMs and PREMs are collected at baseline and every three months (urinary function, sexual function, and PREMs are annual). On the basis of the International Consortium for Health Outcomes Measurement guidelines, IRONMAN uses the following validated instruments: EORTC QLQ-C30 v3, Brief Pain Inventory (severity, impact, and amount of pain), FACT-FPSI 17 (Functional Assessment of Cancer Therapy in patients with advanced prostate cancer), and EPIC-26 (Expanded Prostate Cancer Index Composite Short Form, urinary and sexual function questions). In addition, patients complete the Pittsburgh Sleep Quality Index on sleep quality, quantity, disruptions, and medications. Subjective cognitive function is assessed with questions derived from the Structured Telephone Interview for Dementia Assessment, which has been robustly validated and can identify patients in subclinical stages of cognitive impairment. Androgen deprivation therapy may impair cognitive function although the impact of newer androgen receptor–targeted therapies is unclear. Finally, six questions from the Cancer Australia’s Core Patient Experience Indicators are used to collect data on PREMs. At some US sites and in Nigeria, Kenya, Jamaica, Barbados, and the Bahamas, the CaPTC-AC3 Behavioral and Epidemiological measures collect culturally responsive data from Black patients.

**Physician Questionnaire**

There is a paucity of empirical data evaluating the reasons for treatment selection and discontinuation across oncology

| Specimen                  | Collection Tube | Total Blood Volume, mL |
|--------------------------|-----------------|------------------------|
| Plasma and buffy coat    | (1) Heparin tube| 10                     |
| Whole blood              | (1) EDTA tube   | 3                      |
| cfDNA                    | (1) Streck tube | 10                     |
| RNA                      | (1) PAXgene tube| 2.5                    |

Abbreviation: cfDNA, cell free DNA.
in real-world settings. To address this knowledge gap, we developed a novel questionnaire instrument. After creation of content domains, concepts were elicited through scripted interviews with urologists and medical oncologists in academic and community practices from seven countries with IRONMAN sites, and the draft questionnaire was pilot-tested. The final, English-language questionnaire is completed by the treating physicians at participant enrollment and with each subsequent discontinuation and initiation of a treatment. Domains covered include disease progression, toxicity, and reasons contributing to discontinuation of the prior treatment, as well as patient and tumor characteristics, comorbidities, patient preferences, and nonmedical reasons influencing treatment selection.

**Prostate cancer treatments.** Prostate cancer treatments are documented at enrollment and longitudinally in the clinical database. Data include drug type, dose, dates of initiation and completion, and reason for treatment discontinuation. Treatments include newer agents (Appendix Table A1), older line therapies, and experimental agents.

**Concomitant medications.** Concomitant medications are collected at baseline and every 12 months. Medications include aspirin, nonsteroidal anti-inflammatory drugs, statins, blood pressure lowering medications, diabetes medications, and antidepressants. Baseline information on supplements and multivitamins is collected via TrueNTH.

**RESULTS**

**Clinical, Pathologic, and Outcome Data**

At enrollment, sites provide pathologic and/or clinical stage, Gleason score, dates of prior treatment (prostatectomy, radiation, and hormonal therapy), and prostate-specific antigen level at diagnosis. The ECOG Scale of Performance Status is reported at enrollment and annually thereafter. Progression dates, location of metastases, and prostate-specific antigen are collected throughout the study period. Clinically significant adverse events, ie, serious adverse events and symptomatic skeletal events, including symptomatic pathologic fractures, palliative radiation therapy, palliative surgery, spinal cord compression, and other cancers, are also collected. Mortality (date and cause of death) is ascertained via report from sites, physician questionnaires, or searches of national database.

**Withdrawal From Ironman**

Patients can withdraw participation in IRONMAN at any time, for any reason, and without consequence. If patients wish to discontinue, they are asked whether investigators may continue to collect data elements from their medical

![Site activations and quarterly accruals—US and ex-US sites since study inception.](image-url)
records including overall survival. Data collected before the patient’s withdrawal of consent remain in the database, unless restricted by local regulations. Site staff indicate the date and reason for withdrawal in the database.

Substudies

IRONMAN investigators, collaborators, and industry funders may develop concepts for independent or collaborative substudies leveraging the IRONMAN population and infrastructure. The proposed project must first be scoped by the PCCTC. Depending on its nature, the substudy proposal may be circulated to country lead investigators or applicable working groups for review and comment. If the substudy is determined to be feasible and in accordance with the overall goals and objectives of IRONMAN, the Executive Committee will approve the substudy proposal.

Statistical Considerations

Although the study sample size was not powered for any one specific hypothesis, we seek to enroll sufficient numbers of patients to provide robust estimates in comparing outcomes separately for patients with mHSPC and CRPC, within a country, within racial/ethnic groups, and for clinical and molecular subtypes. The IRONMAN Biostatistics and Data Science working group has been an essential partner in determining the overall sample size of 5,000 patients across the registry. In addition, they have been integral in developing and executing biostatistical analysis plans for each of the study objectives and substudies.

Progress to Date

To date, partnerships have been established and country lead investigators have been identified in all countries; sites in 12 of the 16 countries are open and enrolling. As of July 2022, 2,682 patients have been successfully enrolled—of whom 1,006 were enrolled from US sites. Figure 6 presents site activation and quarterly recruitment totals since study inception. Only 6% of patients have voluntarily withdrawn their participation from the study.

Table 3 presents baseline characteristics of the first 2,682 eligible patients whose demographics are available as of July 2022. At the time of enrollment, 66% of patients had mHSPC and 34% had CRPC. The median (IQR) age at entry is 70 (64-76) years. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five VA Medical Centers in the United States are activated for enrollment to date, and globally, 23% of patients report having served in the military.

Two primary challenges have affected recruitment and study conduct to date—the European Union’s (EU’s) General Data Protection Regulation (GDPR) and the COVID-19 pandemic. GDPR, effective May 2018, contains requirements related to the processing of personal data of individuals who are located within the EU and European Economic Area (EEA). GDPR applies to any organization that is processing personal data of individuals inside the EU/EEA, regardless of where the organization is located. The collection of IRONMAN data from EU/EEA sites is under the purview of GDPR regulations. Although this delayed opening sites in Europe for almost 12 months, the PCCTC has since executed data access agreements containing EU model clauses and designated an EU representative to serve as a trusted third-party contact per GDPR requirements.

### Table 3. Baseline Characteristics of the First 2,682 Eligible Patients Enrolled in the IRONMAN Registry With Reported Baseline Demographics

| Patient Characteristic                              | N = 2,682 |
|-----------------------------------------------------|-----------|
| Median (IQR) age at consent, years                  | 71 (65-77) |
| Median (IQR) age at diagnosis, years                | 70 (64-76) |
| Disease state at entry, No. (%)                     |           |
| mHSPC                                               | 1,763 (66) |
| CRPC                                                | 919 (34)  |
| Race (patient-reported), No. (%)                    |           |
| White                                               | 1,787 (85) |
| African/African American/Black/Black British/Caribbean | 236 (11) |
| Asian/Asian American/Asian British                  | 41 (1.0)  |
| Multiracial                                         | 17 (0.8)  |
| Middle Eastern                                      | 7 (0.3)   |
| Aboriginal                                          | 3 (0.1)   |
| American Indian/Alaskan Native                      | 3 (0.1)   |
| Native Hawaiian or Other Pacific Islander           | 2 (< 0.1) |
| Not reported                                        | 586       |
| Ethnicity (patient-reported), No. (%)               |           |
| Hispanic/Latino                                     | 201 (9)   |
| Not Hispanic/Latino                                 | 1,965 (81) |
| Not reported                                        | 516       |
| Country, No. (%)                                    |           |
| United States                                       | 1,006 (38) |
| Australia                                           | 180 (6.7) |
| Canada                                              | 348 (13)  |
| Switzerland                                         | 153 (5.7) |
| England                                             | 319 (12)  |
| Sweden                                              | 96 (3.6)  |
| Brazil                                              | 52 (1.9)  |
| Spain                                               | 354 (13)  |
| Ireland                                             | 85 (3.2)  |
| Nigeria                                             | 81 (3.0)  |
| Norway                                              | 8 (0.3)   |
| Jamaica (activated April 2022)                      | 0 (0)     |

Abbreviations: CRPC, castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer.

Economic Area (EEA). GDPR applies to any organization that is processing personal data of individuals inside the EU/EEA, regardless of where the organization is located. The collection of IRONMAN data from EU/EEA sites is under the purview of GDPR regulations. Although this delayed opening sites in Europe for almost 12 months, the PCCTC has since executed data access agreements containing EU model clauses and designated an EU representative to serve as a trusted third-party contact per GDPR requirements.
The COVID-19 pandemic has affected IRONMAN in several ways. At almost all US sites, recruitment stopped completely at the beginning of the pandemic. The global impact has been variable given differences in COVID-19 infection, timing, and severity as well as variability in public health policies. Although recruitment in some sites has begun to trend toward prepandemic levels, particularly internationally, recruitment in others remains on hold. The pandemic has delayed opening new sites, including the activation of some sites in the Caribbean and Africa. The PCCTC developed a set of best practices for conducting clinical trials during the pandemic, and the study teams adapted to ensure the safety of its participants, clinicians, and research staff. The COVID-19 pandemic has also disrupted global supply chains, affecting the ability of country-specific biorepositories to reliably obtain the necessary biospecimen collection supplies and materials. As a result, the PCCTC implemented a centralized solution using a US-based vendor to obtain and ship supplies to the country-specific biorepositories.

**Future Directions**

Sixteen countries are currently participating in IRONMAN, and we will seek to expand into additional regions. Although IRONMAN has been successful in recruiting Black patients, we need to continue along this trajectory and enhance recruitment of patients of Hispanic ethnicity and Asian ancestry. Currently, we are not enrolling in Asia or Eastern Europe and have limited representation in South America. This is a limitation of the registry, and we are working to identify opportunities for additional funding and engaging new partners to expand IRONMAN and enroll patients from a broader set of countries. We are in the process of expanding diversity initiatives across each country by identifying specific aspects of diversity that are important (eg, socioeconomic, private v public practices, and geography) and plan to work with each country lead investigator to set benchmarks for success.

We aim to enhance data collection types and repositories and conduct additional substudies. For example, we have institutional review board approval in place to collect archival prostate tumor tissue and clinical imaging assessments. Additional funding is needed to establish and maintain the infrastructure for these repositories.

A key unmet need among our LMIC/SIDS partners is the lack of accessibility to advanced prostate cancer therapies. We intend to establish initiatives aimed at increasing therapeutic access to patients in IRONMAN through diverse partnerships with pharmaceutical companies, foundations, governmental agencies, patients, and other stakeholders.

**DISCUSSION**

The number of people globally diagnosed with advanced prostate cancer is considerable and growing because of advances in earlier detection and treatment, leading to longer survival. The treatment landscape has changed rapidly and will continue to do so. Randomized prospective trials to test all potential combinations in practice patterns are not feasible, but real-world evidence, such as that generated by IRONMAN, can help to inform potential optimal sequences of agents and identify subgroups of patients who would benefit the most.

Advanced prostate cancer and side effects of treatments likely affect quality-of-life issues. Relatively little is currently known about the real-life quality-of-life experience of these patients, beyond the narrowly defined patient populations within trials submitted for regulatory approvals. IRONMAN can elucidate which populations experience quality-of-life issues related to their treatments or disease by recruiting a diverse population and maintaining high levels of PROMs/ PREMs compliance.

Generating real-world evidence will require data collection to be timely, thorough, and accurate. Although the COVID-19 pandemic, introduction of GDPR, and global differences in clinical research standards have posed challenges for recruitment and data collection, IRONMAN’s diversified governance structure is well-positioned to meet these challenges and succeed in creating a valuable resource for the prostate cancer community.
CORRESPONDING AUTHOR
Lorelei A. Mucci, ScD, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Room 920, Boston, MA 02115; e-mail: lmucci@hsph.harvard.edu.

EQUAL CONTRIBUTION
L.A.M. and J.V. shared first authors; P.V., P.W.K., and D.J.G. shared last authors.

PRIOR PRESENTATION
Presented as posters at ASCO GU Symposium 2022, San Francisco, CA, February 17-19, 2022 and at the 26th Annual PCF Scientific Retreat, Carlsbad, CA, October 24-26, 2019.

AUTHOR CONTRIBUTIONS
Conception and design: Lorelei A. Mucci, Jacob Vinson, Simon G. Anderson, Deborah Enting, André P. Fay, Ray McDermott, Folakemi T. Odedina, Charles Waihenya, Konrad H. Stopsack, Terry Hyslop, Paul Villanti, Philip W. Kantoff, Daniel J. George
Administrative support: Lorelei A. Mucci, Theresa Gold, Anders Bjartell
Provision of study materials or patients: Simone Badal, Kim N. Chi, Ian D. Davis, Deborah Enting, André P. Fay, Joaquin Mateo, Folakemi T. Odedina, David Olmos, Aurelius Omlin, Ademola A. Popoola, Robin Roberts, Charles Waihenya
Collection and assembly of data: Lorelei A. Mucci, Jacob Vinson, Theresa Gold, Travis Gerke, Julie Filipenko, Rebecca M. Green, Simone Badal, Anders Bjartell, Kim N. Chi, Ian D. Davis, Deborah Enting, André P. Fay, John Lazarus, Joaquin Mateo, Ray McDermott, David Olmos, Aurelius Omlin, Ademola A. Popoola, Camille Ragin, Robin Roberts, Kjell M. Russnes, Charles Waihenya
Data analysis and interpretation: Lorelei A. Mucci, Jacob Vinson, Travis Gerke, Julie Filipenko, Simon G. Anderson, Simone Badal, Deborah Enting, André P. Fay, Ray McDermott, Folakemi T. Odedina, Charles Waihenya, Terry Hyslop, Philip W. Kantoff, Daniel J. George
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Julie Filipenko
Employment: Organon
Stock and Other Ownership Interests: Organon
Deborah Enting
Honorary: Astellas Pharma
Consulting or Advisory Role: Bayer
Speakers’ Bureau: Janssen Oncology
David Olmos
Honorary: Janssen, Bayer, Astellas Pharma (Inst)
Consulting or Advisory Role: Janssen (Inst), AstraZeneca (Inst), Clovis Oncology, Bayer (Inst), Daiichi Sankyo, MSD Oncology

Research Funding: AstraZeneca (Inst), Bayer (Inst), Janssen (Inst), Genentech/Roche (Inst), Pfizer (Inst), Astellas Medication (Inst), Tokai Pharmaceuticals (Inst), MSD Oncology (Inst)
Travel, Accommodations, Expenses: Bayer, Janssen, Ipsen, Astellas Pharma, Roche, AstraZeneca Spain

Ademola A. Popoola
Honorary: Janssen Oncology

Terry Hyslop
Consulting or Advisory Role: AbbVie
Travel, Accommodations, Expenses: AbbVie

Kim N. Chi
Honorary: Janssen, Astellas Pharma, Bayer, AstraZeneca, Roche, Merck
Consulting or Advisory Role: ESSA, Astellas Pharma, Janssen, Sanofi, Amgen, Bayer, AstraZeneca, Roche, POINT Biopharma, Daiichi Sankyo, Merck, Constellation Pharmaceuticals
Research Funding: Janssen (Inst), Astellas Pharma (Inst), Bayer (Inst), Sanofi (Inst), Bristol Myers Squibb (Inst), Merck (Inst), Roche (Inst), AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), ESSA (Inst)
Expert Testimony: AstraZeneca, Novartis

Ray McDermott
Honorary: Bayer, Sanofi, Janssen, Astellas Pharma, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Novartis, Clovis Oncology
Speakers’ Bureau: MSD Oncology
Research Funding: Sanofi (Inst), Janssen (Inst), Bayer (Inst), Astellas Pharma (Inst)
Travel, Accommodations, Expenses: Pfizer, Janssen-Cilag, Roche, Ipsen

Philip W. Kantoff
Employment: Convergent Therapeutics
Leadership: Context Therapeutics, XLink, Convergent Therapeutics
Stock and Other Ownership Interests: Placon, Druggability Technologies, Context Therapeutics, Seer, Cogent Biosciences, Mirati Therapeutics, PrognomiQ, SynDevRx, XLink
Consulting or Advisory Role: Janssen, Merck, OncoCellIMDx, Genetech/Roche, Tarveda Therapeutics, Druggability Technologies, Progenity, Seer, Anji Pharma, Candel Therapeutics, Context Therapeutics, PrognomiQ, SynDevRx, Veru, XLink
Research Funding: Janssen, Merck, OncoCellIMDx, Genetech/Roche, Tarveda Therapeutics, Druggability Technologies, Progenity, Seer, Anji Pharma, Candel Therapeutics, Context Therapeutics, PrognomiQ, SynDevRx, Veru, XLink

Patents, Royalties, Other Intellectual Property: Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality, Predicting and Treating Prostate Cancer, Methods for Predicting Likelihood of Responding to Treatment, Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality, Drug Combinations to Treat Cancer, Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent), Up-to-Date Royalties, Wolters Kluwer Royalties, Methods and Kits for Determining Sensitivity to Cancer Treatment, Composition and Methods for Screening and Diagnosis of Prostate Cancer
Other Relationship: Bayer
Open Payments Link: https://openpaymentsdata.cms.gov/physician/55315/summary

André P. Fay
Honorary: Pfizer, Novartis, Bristol Myers Squibb, AstraZeneca, Roche, Ipsen, Janssen Oncology, MSD
Consulting or Advisory Role: Novartis, Roche, Pfizer, Merck Sharp & Dohme, AstraZeneca, Ipsen

Aurelius Omlin
Consulting or Advisory Role: Astellas Pharma (Inst), Bayer (Inst), Sanofi (Inst), Roche (Inst), Janssen (Inst), MSD (Inst), Molecular Partners (Inst), Pfizer (Inst), AstraZeneca (Inst)
Speakers’ Bureau: Bayer (Inst), Astellas Pharma (Inst), Janssen-Cilag (Inst), Tripple AAA
Research Funding: Teva (Inst), Janssen (Inst)
Travel, Accommodations, Expenses: Sanofi, Bayer, Astellas Pharma, Janssen
Lorelei A. Mucci
Employment: Convergent Therapeutics
Leadership: Context Therapeutics, Genentech/Roche, Merck
Stock and Other Ownership Interests: Convergent Therapeutics, Context Therapeutics, Druggability Technologies, Placon, Seer, Tarveda Therapeutics
Consulting or Advisory Role: Bayer, Bavarian Nordic, GE Healthcare, Janssen Oncology, New England Research Institutes, OncoCellMDx, Progenity, Sanofi
Research Funding: Sanofi (Inst), Astellas Pharma (Inst), Bayer (Inst), Janssen (Inst), AstraZeneca (Inst)
Anders Bjartell
Stock and Other Ownership Interests: Lidds, WntResearch, Glaetone Pharma
Consulting or Advisory Role: Astellas Pharma, Bayer, Janssen-Cilag, AstraZeneca, Merck, Sandoz, Recordati
Speakers’ Bureau: Janssen-Cilag, Astellas Pharma, Ipsen
Research Funding: Ferring (Inst), Astellas Pharma (Inst), Bayer (Inst)
Travel, Accommodations, Expenses: Astellas Pharma
Joaquin Mateo
Consulting or Advisory Role: AstraZeneca, Roche, MSD, Amgen, Pfizer
Speakers’ Bureau: AstraZeneca, Janssen, Pfizer, Guardant Health
Research Funding: AstraZeneca (Inst), Pfizer
Travel, Accommodations, Expenses: AstraZeneca
Camille Ragin
Speakers’ Bureau: Pfizer
Research Funding: Pfizer (Inst)
Rebecca M. Green
Research Funding: PCCTC (Inst)
Theresa Gold
Employment: Arvinas
Stock and Other Ownership Interests: Arvinas
Travel, Accommodations, Expenses: Arvinas
Ian D. Davis
Research Funding: Astellas Pharma (Inst), Pfizer (Inst), Roche/Genentech (Inst), MSD Oncology (Inst), AstraZeneca (Inst), Janssen Oncology (Inst), Eisai (Inst), Bayer (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), Movember Foundation (Inst), Exelixis (Inst), Ipsen (Inst), Medivation (Inst), Seattle Genetics (Inst)
Patents, Royalties, Other Intellectual Property: International Patent Application No.: PCT/US2004/032,147 (NY-ESO-1) through Ludwig Institute for Cancer Research
Daniel J. George
Leadership: Capio BioSciences
Honoraria: Sanofi, Bayer, Exelixis, EMD Serono, OncLive, Pfizer, UnToday, Acceleron Pharma, American Association for Cancer Research, Axess Oncology, Janssen Oncology, Millennium Medical Publishing
Consulting or Advisory Role: Bayer, Exelixis, Pfizer, Sanofi, Astellas Pharma, Innocrin Pharma, Bristol Myers Squibb, Genentech, Janssen, Merck Sharp & Dohme, Myovant Sciences, AstraZeneca, Michael J. Hennessy Associates, Constellation Pharmaceuticals, Physicians’ Education Resource, Propella Therapeutics, RevHealth, xCures
Speakers’ Bureau: Sanofi, Bayer, Exelixis
Research Funding: Exelixis (Inst), Janssen Oncology (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Actera Pharma (Inst), Bayer (Inst), Dendreon (Inst), Innocrin Pharma (Inst), Calithera Biosciences (Inst), Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses: Bayer, Exelixis, Mercck, Pfizer, Sanofi, Janssen Oncology, UnToday
No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
The IRONMAN registry was principally funded by the Movember Foundation. Additional funding was provided by Amgen, Astellas, AstraZeneca, Bayer, Janssen, Merck, and Sanofi/Genzyme. We are grateful to the IRONMAN participants for their ongoing commitment to the study. We would like to acknowledge the site investigators and clinical research coordinators involved in the study.

REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021
2. Miller KD, Nogueira L, Mariotto AB, et al: Cancer treatment and survivorship statistics. CA Cancer J Clin 69:363-385, 2019
3. Chowdhury S, Bjartell A, Lumen N, et al: Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: The prostate cancer registry. Target Oncol 15:301-315, 2020
4. Kantoff PW, Higano CS, Shore ND, et al: Spinalucl-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
5. Hussain M, Mateo J, Fizazi K, et al: Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383:2345-2357, 2020
6. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
7. Hussain M, Fizazi K, Saad F, et al: Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 383:2345-2357, 2020
8. Ryan CJ, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
9. Fizazi K, Shore N, Tammela TL, et al: Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383:1040-1049, 2020
10. de Wit R, de Bono J, Sternberg CN, et al: Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381:2506-2518, 2019
11. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
12. Abida W, Patnaik A, Campbell D, et al: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38:3763-3772, 2020
13. Shore ND, Saad F, Cookson MS, et al: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187-2196, 2020
14. Prasad V, Kaestner V, Mailankody S: Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol 4:157-158, 2018
15. Teo MY, Rathkopf DE, Kantoff P: Treatment of advanced prostate cancer. Annu Rev Med 70:479-499, 2019
16. Rencosk EM, Bazzi LA, McKay RR, et al: Diversity of enrollment in prostate cancer clinical trials: Current status and future directions. Cancer Epidemiol Biomarkers Prev 29:1374-1380, 2020
17. McKay RR, Gold T, Zarif JC, et al: Tackling diversity in prostate cancer clinical trials: A report from the diversity working group of the IRONMAN registry. JCO Glob Oncol 7:495-505, 2021
18. National Cancer Institute: SEER Cancer Statistics Review, 1975-2013. Bethesda, MD, National Cancer Institute, 2016
19. Chornokur G, Dalton K, Borysova ME, et al: Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 71:985-997, 2011
20. Hoffman RM, Gilliland FD, Eley JW, et al: Racial and ethnic differences in advanced-stage prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 93:388-395, 2001
21. Oakley-Girvan I, Kotelon LN, Gallagher RP, et al: Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health 93:1753-1759, 2003
22. Jones BA, Liu WL, Araujo AB, et al: Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 17:2825-2834, 2008
23. Pettaway CA, Troncoso P, Ramirez EI, et al: Prostate specific antigen and pathological features of prostate cancer in black and white patients: A comparative study based on radical prostatectomy specimens. J Urol 160:437-442, 1998
24. American Cancer Society: Cancer Facts & Figures for African Americans 2019-2021. Atlanta, GA, American Cancer Society, 2019
25. George S, Duran N, Norris K: A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health 104:e16-e31, 2014
26. Dasgupta P, Baade PD, Atiken JF, et al: Geographical variations in prostate cancer outcomes: A systematic review of international evidence. Front Oncol 9:238, 2019
27. Dess RT, Hartman HE, Mahal BA, et al: Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 5:975-983, 2019
28. Morgans AK, van Bommel AC, Stowell C, et al: Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach. Eur Urol 68:891-898, 2015
29. Scher HI, Morris MJ, Stadler WM, et al: Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418, 2016
30. Go RC, Duke LW, Harrell LE, et al: Development and validation of a Structured Telephone Interview for Dementia Assessment (STIDA). The NIMH genetics initiative. J Geriatr Psychiatry Neurol 10:161-167, 1997
31. Amariglio RE, Townsend MK, Grodstein F, et al: Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc 59:1612-1617, 2011
32. Jessen F, Amariglio RE, van Boxtel M, et al: A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's Dement 10:844-852, 2014
33. Amariglio RE, Mormino EC, Pietras AC, et al: Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly. Neurology 85:56-62, 2015
34. Donovan NJ, Amariglio RE, Zolfer AS, et al: Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry 22:1642-1651, 2014
35. Sun M, Cole AP, Hanna N, et al: Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: A systematic review and meta-analysis. J Urol 199:1417-1425, 2018
36. Odedina FT, Ragin C, Martin D, et al: Standardized global behavioral and epidemiological measures for prostate cancer studies in Black men. Cancer Health Disparities 4:e1-e16, 2020
### TABLE A1. FDA-Approved Medications for the Treatment of Patients With mHSPC or CRPC Since 2004

| Drug                   | Brand Name | Company                        | Drug Class         | Indication                          |
|------------------------|------------|--------------------------------|-------------------|-------------------------------------|
| Docetaxel              | Taxotere   | Sanofi (Paris, France)         | Chemotherapy       | mCRPC                               |
| Cabazitaxel            | Jevtana    | Sanofi (Paris, France)         | Chemotherapy       | mCRPC postdocetaxel                 |
| Sipuleucel-T           | Provenge   | Dendreon (Seal Beach, CA)      | Immunotherapy      | mCRPC                               |
| Denosumab              | Xgeva      | Amgen (Thousand Oaks, CA)      | Bone health agent  | Prevention of skeletal-related events|
| Abiraterone acetate    | Zytiga     | Janssen (Beerse, Belgium)      | AR antagonist      | mCRPC                               |
| Radium 223             | Xofigo     | Bayer (Leverkusen, Germany)    | Alpha-emitting radio pharmaceutical | mCRPC with bone metastases          |
| Pembrolizumab          | Keytruda   | Merck (Kenilworth, NJ)         | Immunotherapy      | MSI-H or dMMR solid tumors          |
| Enzalutamide           | Xtandi     | Astellas (Chuo City, Tokyo, Japan) | AR inhibitor | mHSPC CRPC                          |
| Apalutamide            | Erleada    | Janssen (Beerse, Belgium)      | AR inhibitor       | nmCRPC                              |
| Darolutamide           | Nubeqa     | Bayer (Leverkusen, Germany)    | AR inhibitor       | nmCRPC                              |
| Rucaparib              | Rubraca    | Clovis oncology (Boulder, CO)  | PARP inhibitor     | mCRPC post-taxane, post-AR with BRCA mutations |
| Olaparib               | Lynparza   | AstraZeneca (Cambridge, United Kingdom) and Merck (Kenilworth, NJ) | PARP inhibitor | mCRPC post-AR with homologous recombination repair gene mutations |
| Lu-177-PSMA-617         | Pluvicto   | Novartis (Basel, Switzerland)  | PSMA-directed radioligand | mCRPC post-taxane, post-AR          |

Abbreviations: AR, androgen receptor; CRPC, castration-resistant prostate cancer; dMMR, mismatch repair–deficient; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; MSI-H, microsatellite instability-high; nmCRPC, nonmetastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase.